Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
Jonathan Hoggatt,1 Tiffany A Tate,1 Louis M Pelus2 1Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA; 2Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA Abstract: Chemotherapy, irradiation, and other age...
Guardado en:
Autores principales: | Hoggatt J, Tate TA, Pelus LM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d1e3f98579804b9c81d3d3eb9b386d6e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
por: Hoggatt J, et al.
Publicado: (2015) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia R, et al.
Publicado: (2016) -
Review on lipegfilgrastim
por: Gasparic M, et al.
Publicado: (2015) -
Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli D, et al.
Publicado: (2016) -
Lamotrigine‐induced neutropenia after high‐dose concomitant initiation with phenytoin
por: Muhammad Salem, et al.
Publicado: (2021)